Alnylam Pharmaceuticals Inc ALNY:NASDAQ

Last Price$124.23NASDAQ Previous Close - Last Trade as of 3:59PM ET 12/05/19
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$124.00 (2)
Ask (Size)$143.21 (5)
Day Low / HighN/A - N/A
Volume980.1 K
 

View Biotechnology IndustryPeer Comparison as of 12/05/2019

 

Alnylam Pharmaceuticals Inc ( NASDAQ )

Price: $124.23
Change: +2.25 (1.84%)
Volume: 980.1 K
3:59PM ET 12/05/2019
 
 

Biomarin Pharmaceutical Inc ( NASDAQ )

Price: $80.08
Change: -1.21 (1.49%)
Volume: 1.1 M
3:59PM ET 12/05/2019
 
 

Exact Sciences Corp ( NASDAQ )

Price: $83.61
Change: +0.61 (0.73%)
Volume: 1.3 M
4:00PM ET 12/05/2019
 
 

Neurocrine Biosciences Inc ( NASDAQ )

Price: $116.48
Change: -2.09 (1.76%)
Volume: 647.6 K
4:00PM ET 12/05/2019
 
 

Ionis Pharmaceuticals Inc ( NASDAQ )

Price: $64.53
Change: -0.47 (0.72%)
Volume: 872.5 K
4:00PM ET 12/05/2019
 

Read more news Recent News

Analyst Actions: Stifel Nicolaus Raises Price Target for Buy-Rated Alnylam Pharmaceuticals to $136 From $126
1:54PM ET 11/25/2019 MT Newswires

Alnylam Pharmaceuticals (ALNY) has an average buy rating among analysts with a $58 average price target. Price: 113.31, Change: +6.39, Percent Change:...

Analyst Actions: JP Morgan Raises Price Target for Alnylam Pharmaceuticals to $116 From $103, Maintains Overweight Rating
1:53PM ET 11/25/2019 MT Newswires

Alnylam Pharmaceuticals (ALNY) has an average buy rating among analysts with a $58 average price target. Price: 113.40, Change: +6.49, Percent Change:...

Analyst Actions: Jefferies Boosts Price Target for Buy-Rated Alnylam Pharmaceuticals to $123 From $115
1:50PM ET 11/25/2019 MT Newswires

Alnylam Pharmaceuticals (ALNY) has an average buy rating among analysts with a $58 average price target. Price: 113.82, Change: +6.91, Percent Change:...

Analyst Actions: SVB Leerink Raises Price Target for Alnylam Pharmaceuticals to $78 From $76, Maintains Market Perform Rating
1:49PM ET 11/25/2019 MT Newswires

Alnylam Pharmaceuticals (ALNY) has an average buy rating among analysts with a $58 average price target. Price: 113.81, Change: +6.90, Percent Change:...

Company Profile

Business DescriptionAlnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA. View company web site for more details
Address675 West Kendall Street
Cambridge, Massachusetts 02142
Phone+1.617.551.8200
Number of Employees1,065
Recent SEC Filing11/26/20194
Chief Executive Officer & DirectorJohn M. Maraganore
PresidentBarry E. Greene
Chief Operating Officer & Executive Vice PresidentYvonne L. Greenstreet
Chief Financial & Accounting OfficerJeffrey Poulton

Company Highlights

Price Open$121.66
Previous Close$124.23
52 Week Range$60.27 - 125.59
Market Capitalization$13.9 B
Shares Outstanding111.5 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement02/06/2020

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$7.82
Beta vs. S&P 500N/A
Revenue$74.9 M
Net Profit Margin-485.73%
Return on Equity-52.88%

Analyst Ratings as of 11/26/2019

Buy
15
Overweight
1
Hold
3
Underweight
1
Sell
1
Consensus RecommendationConsensus Icon
Powered by Factset